(Q30458930)

21 June 2017

title

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety (English)

1 reference

relapsing-remitting multiple sclerosis

21 June 2017

main subject

0 references

0 references

1 reference

1

David E Jones

1 reference

21 June 2017

Myla D Goldman

2

1 reference

21 June 2017

publication date

22 August 2014

1 reference

Expert Review of Clinical Immunology

21 June 2017

published in

1 reference

21 June 2017

volume

10

1 reference

21 June 2017

issue

10

1 reference

21 June 2017

page(s)

1281-1291

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

21 June 2017

1 reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Immune status following alemtuzumab treatment in human CD52 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Immune competence after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Melanoma following treatment with alemtuzumab for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.951332

10.1586/1744666X.2014.951332

21 January 2018

Identifiers

DOI

1 reference

release_vgcrjhkxkzdr5oei3bcluyd32m

21 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vgcrjhkxkzdr5oei3bcluyd32m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference